ArticleFrontiers in neuroscience2025
Exploring ischemic stroke based on the ferroptosis perspective: ECH1 may serve as a new biomarker and therapeutic target.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke (IS), the leading stroke subtype (∼87%), arises from vascular occlusions, triggering brain necrosis through ischemia-reperfusion injury. Ferroptosis, an iron-driven cell death via Fe Methods: We integrated transcriptome data from the GEO database with preprocessing and normalization. Hub genes were screened using differential expression analysis and machine learning algorithms. Subsequently, genes were further filtered by mendelian randomization and also validated using transient middle cerebral artery occlusion (tMCAO) model. Results: Ferroptosis-related genes in the IS group showed higher expression compared with the healthy control group. Using differential expression analysis and machine learning algorithms, 12 potential hub genes were successfully screened. Mendelian randomization analysis further confirmed the causal association between ECH1 and stroke. In the tMCAO mouse model, ECH1 mRNA levels were down-regulated, consistent with the results of the clinical samples. Conclusion: In this study, taking ferroptosis as an entry point, ECH1 may serve as a potential peripheral blood biomarker and therapeutic target for IS through multidimensional validation, providing a basis for the development of relevant precision diagnostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.